No abstract

Professor of Mechanical Engineering and director of the Hybrid Vehicles Integration Laboratory. He has been teaching at the undergraduate and graduate level for over 30 years. He teaches Machine Design, Automotive Design, Machine Design Capstone, Automotive Design Capstone, Design Optimization, Advanced Mechanics of Materials, linear and Nonlinear Finite Element analysis, and Design for manufacturability. He has been a PI and Co-PI on several research grants and a consultant to several engineering corporations. He has over seventy research papers in addition to several patents. Steven Beyerlein, University of Idaho Professor of Mechanical Engineering. He has been teaching Sophomore Design, Senior Design, and Combustion Engine Systems, testing of catalytic engine systems, conducting action research in the college classrooms, teaching and documenting open-ended problem solving, and designing professional development activities. He is a Member of the Transferable Integrated Design Engineering Education (TIDEE) consortium that produced and field tested a three component Design Team Readiness Assessment. He is a Co-PI on the NSF Enriched Learning Environment grant with primary responsibility for the formation and ongoing development of a community of research-based classroom practitioners at the

Rationally targeted therapies have transformed cancer treatment, but many patients develop resistance through bypass signaling pathway activation. PF-07284892 (ARRY-558) is an allosteric SHP2 inhibitor designed to overcome bypass-signaling-mediated resistance when combined with inhibitors of various oncogenic drivers. Activity in this setting was confirmed in diverse tumor models. Patients with ALK fusion–positive lung cancer, BRAFV600E-mutant colorectal cancer, KRASG12D-mutant ovarian cancer, and ROS1 fusion–positive pancreatic cancer who previously developed targeted therapy resistance were treated with PF-07284892 on the first dose level of a first-in-human clinical trial. After progression on PF-07284892 monotherapy, a novel study design allowed the addition of oncogene-directed targeted therapy that had previously failed. Combination therapy led to rapid tumor and circulating tumor DNA (ctDNA) responses and extended the duration of overall clinical benefit. Significance: PF-07284892–targeted therapy combinations overcame bypass-signaling-mediated resistance in a clinical setting in which neither component was active on its own. This provides proof of concept of the utility of SHP2 inhibitors in overcoming resistance to diverse targeted therapies and provides a paradigm for accelerated testing of novel drug combinations early in clinical development. See related commentary by Hernando-Calvo and Garralda.

No abstract

No abstract